Celcuity Heads Into Launch-Defining Print With Bears Still Heavily Positioned
CELC enters its Q2 earnings release today carrying one of the most contested short books in small-cap biotech — and a month of selling that has left the stock down 17% to $86.60. Short sellers remain a dominant force.…